Cost of Compounded Rapamycin: 2025 Pricing, Insurance, and What to Expect

What Does Compounded Rapamycin Actually Cost Per Month?

Compounded rapamycin at longevity-oriented telehealth pharmacies runs $40, $150 per month for the doses most physicians prescribe off-label. The exact figure depends on dose strength, capsule count, and whether the pharmacy charges a compounding fee separately from the drug cost. A prescription for 2 mg weekly (eight 1-mg capsules per month, roughly) lands closer to $40, $60, while a 5 mg weekly protocol using 20 capsules per month climbs toward $100, $150.

Pricing varies because compounded drugs are not subject to the same price transparency rules as FDA-approved branded products. A 503A pharmacy (the most common type, which fills patient-specific prescriptions) sets its own compounding fees. The American Pharmacists Association distinguishes 503A pharmacies, which operate under state boards of pharmacy, from 503B outsourcing facilities regulated more directly by the FDA [1]. Both can legally compound sirolimus when a licensed prescriber writes the order, but 503A pharmacies dominate the direct-to-patient longevity market.

For comparison, brand-name Rapamune (sirolimus, Pfizer/Wyeth) has a list price of roughly $900, $3,000 per month depending on the transplant dose, which ranges from 2 mg to 15 mg daily [2]. Longevity protocols use once-weekly dosing at 1 to 6 mg, so the monthly pill count is far lower, but retail pharmacies still price Rapamune per-tablet rather than per-week. GoodRx shows generic sirolimus 1 mg tablets at approximately $35, $70 for 30 tablets at major chains as of mid-2025, making the monthly cost of a 2 mg weekly protocol roughly $3, $5 in raw pill cost before dispensing fees [3]. Compounding pharmacies bundle the labor, packaging, and ingredient markup into one quoted price, which is why their per-capsule rate appears higher even though the total monthly spend is lower than retail Rapamune.

How Do Insurance Companies Handle Off-Label Rapamycin?

Insurance almost never covers rapamycin prescribed solely for longevity or anti-aging purposes. This is a direct consequence of how U.S. payers define medical necessity. Most commercial plans require an FDA-approved indication tied to a documented diagnosis code (ICD-10). Longevity does not have an ICD-10 code.

The FDA approved sirolimus (Rapamune) in 1999 for prophylaxis of organ rejection in renal transplant patients [4]. Coverage for that indication is routine. Off-label use for longevity, age-related immune decline, or mTORC1 inhibition falls outside that approval, and the Centers for Medicare and Medicaid Services (CMS) generally does not reimburse compounded drugs unless specific criteria are met [5]. Commercial insurers follow similar logic. A prior authorization request citing "longevity" or "healthspan extension" will almost certainly be denied on the first submission.

Two narrow exceptions exist. First, patients who have an on-label condition (such as lymphangioleiomyomatosis, for which sirolimus is FDA-approved under the brand Kymriah/Hyftor in related indications) may receive coverage for the drug itself, though not for compounding costs. Second, some flexible spending accounts (FSAs) and health savings accounts (HSAs) allow reimbursement for prescribed compounded medications, including off-label ones, as long as the prescription is written by a licensed provider [6]. Patients should confirm their specific plan document before assuming HSA eligibility.

The practical advice: assume full out-of-pocket cost, build it into your budget at $50, $150 per month, and check whether your HSA administrator accepts compounded drug receipts.

What Drives the Price Difference Between Pharmacies?

Three factors explain most of the price variation across compounding pharmacies: ingredient sourcing, overhead structure, and whether the pharmacy charges a telehealth consultation fee bundled with the prescription.

Sirolimus active pharmaceutical ingredient (API) is purchased by compounding pharmacies from FDA-registered API suppliers. The cost of the raw API for a 2 to 5 mg weekly longevity dose is genuinely low, often under $5 per month at scale. The rest of the quoted price covers pharmacist labor, quality testing, capsule fills, labeling, and shipping. Pharmacies that operate a vertically integrated telehealth platform typically embed the provider visit fee ($75, $200 per year for follow-up) into a subscription model, making the per-month cost appear higher but the all-in annual cost potentially lower than paying separately for visits and prescriptions.

Telehealth longevity clinics charging $80, $120 per month usually include quarterly lab review, dose adjustment consults, and compounded medication in one flat rate. Stand-alone compounding pharmacies that require a separate prescriber charge $40, $70 for the medication and bill visits separately. Neither model is inherently superior; the right choice depends on how much clinical oversight a patient wants. The FDA recommends patients verify that a compounding pharmacy is state-licensed and, for 503B facilities, appears on the FDA's registered outsourcing facility list [7].

What Does the Science Say About the Doses Being Prescribed?

The longevity dosing rationale comes from a small number of human trials and a large body of animal data. Lifespan extension in genetically heterogeneous mice given rapamycin was first reported by the National Institute on Aging Interventions Testing Program (ITP) in 2009, where mice starting the drug at 600 days of age (equivalent to roughly age 60 in humans) showed median lifespan increases of 14% in females and 9% in males [8]. The ITP has since replicated this finding across three independent sites in multiple cohorts.

The most-cited human trial is Mannick et al. (2014), published in Science Translational Medicine, in which 218 healthy elderly volunteers received the mTORC1 inhibitor RAD001 (everolimus, a rapamycin analog) at 0.5 mg daily, 5 mg weekly, or 20 mg weekly for six weeks before influenza vaccination. The 5 mg weekly group showed a 20% improvement in vaccine response and a reduction in the proportion of CD4+ and CD8+ T cells expressing the aging marker PD-1 (P<0.05 for both endpoints) [9]. This trial is frequently cited to justify once-weekly low-dose rapamycin in humans, even though the drug used was everolimus, not sirolimus.

The PEARL trial (NCT04488601), a randomized, double-blind, placebo-controlled study of sirolimus 5 mg once weekly in healthy adults aged 50, 85, has completed enrollment and preliminary data suggest tolerability comparable to placebo at this dose, though peer-reviewed results are pending as of mid-2025 [10]. Until PEARL publishes its primary endpoints, prescribers are working from indirect evidence and extrapolation from the Mannick data.

The HealthRX clinical team uses the following decision framework when evaluating patients for compounded rapamycin:

HealthRX Compounded Rapamycin Candidacy Framework (v1.0, July 2025)

| Tier | Criteria | Suggested Starting Dose | |------|----------|------------------------| | Standard candidate | Age 40+, no active infection, not planning surgery within 90 days, fasting glucose <100 mg/dL, CBC and CMP within normal limits | 1 to 2 mg once weekly | | Elevated caution | Borderline immunosuppression, history of recurrent infections, on other immunomodulating agents | Hold or 1 mg once weekly with monthly CBC | | Contraindicated | Active infection, planned major surgery, pregnancy, known hypersensitivity to sirolimus, concurrent strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) | Do not prescribe |

Dose titration above 5 mg weekly requires documented rationale and repeat metabolic labs every 90 days per this framework.

How Does Compounded Rapamycin Cost Compare to NMN Supplements?

NMN (nicotinamide mononucleotide) supplements cost $40, $120 per month for 500, 1 to 000 mg daily doses from reputable third-party-tested brands in 2025 to 2026. That price range overlaps almost exactly with compounded rapamycin at standard longevity doses. The comparison matters because some patients budget a fixed monthly amount for longevity interventions and need to choose between categories.

The mechanistic difference is significant. NMN acts as an NAD+ precursor. A randomized, double-blind trial by Yoshino et al. (2021) in Science (N=25 postmenopausal women with prediabetes) found that 250 mg/day NMN for 10 weeks improved muscle insulin signaling and increased skeletal muscle NAD+ metabolome concentrations compared to placebo, though the clinical magnitude was modest [11]. Rapamycin, by contrast, inhibits mTORC1, a nutrient-sensing kinase whose chronic activation is mechanistically linked to cellular senescence and aging in a broader range of tissue types [12].

Neither compound has a completed Phase III longevity trial in humans. Patients should understand both are being used on mechanistic and preclinical grounds, not on the basis of definitive clinical evidence. The FDA does not regulate NMN as a drug; it attempted to block NMN's reclassification as a dietary supplement given prior IND filing by Metro International Biotech, though enforcement remains unsettled [13].

What Are the Real Risks at Longevity Doses?

At 1 to 6 mg once weekly, the adverse effect profile differs substantially from the daily transplant doses (2 to 15 mg/day) where severe immunosuppression is expected. Mouth sores (aphthous ulcers) are the most commonly reported side effect at low weekly doses, occurring in roughly 20 to 30% of patients in small observational series. Delayed wound healing is a documented pharmacological effect of mTOR inhibition even at low doses [14].

Infection risk at once-weekly longevity doses appears low but is not zero. The package insert for Rapamune warns of increased susceptibility to infection, including opportunistic pathogens, at all doses [2]. Patients undergoing elective surgery should discontinue rapamycin at least four weeks before the procedure based on transplant-derived guidance, which the HealthRX medical team applies conservatively to longevity patients as well.

Lipid abnormalities, including elevated triglycerides and LDL cholesterol, occur in a minority of patients at transplant doses. At once-weekly dosing, clinically significant lipid changes are less frequently reported, but baseline and follow-up fasting lipid panels are standard practice. Sirolimus is also a substrate and inhibitor of CYP3A4 and P-glycoprotein, creating interaction potential with statins (especially simvastatin and lovastatin), antifungals, and macrolide antibiotics [2].

How to Find a Legitimate Compounding Pharmacy for Rapamycin

Not all compounding pharmacies meet the same quality standards. The FDA's list of registered 503B outsourcing facilities is publicly searchable and updated regularly [7]. For 503A pharmacies, the relevant accreditation bodies are the Pharmacy Compounding Accreditation Board (PCAB) and state boards of pharmacy. PCAB-accredited pharmacies have voluntarily undergone independent quality inspections and are generally a safer choice for compounded drugs that lack the standardized manufacturing oversight of FDA-approved products.

A legitimate pharmacy will provide a certificate of analysis (COA) for the batch of compounded sirolimus on request. The COA should confirm potency, sterility testing (for injectables), and absence of identified contaminants. Oral capsules require potency testing but not sterility testing under USP Chapter 795 standards [1]. Ask for the COA before the first fill.

Red flags include pharmacies that do not require a valid prescription, those that ship controlled substances or compounded drugs to states where they are not licensed, and any provider offering rapamycin without baseline labs. The FDA has issued warning letters to compounding pharmacies that produced sirolimus without adequate quality controls, underscoring that not all compounded products are equivalent [4].

What Labs Should Be Ordered Before and During Rapamycin Use?

Baseline labs before starting compounded rapamycin at longevity doses should include a complete blood count (CBC), comprehensive metabolic panel (CMP), fasting lipid panel, fasting glucose, HbA1c, and urinalysis. This mirrors the pre-treatment workup recommended in the Rapamune prescribing information for transplant patients, scaled to the lower-risk longevity context [2].

Follow-up labs at 90 days should repeat CBC, CMP, and lipids. A sirolimus trough level (whole blood, drawn 24 hours after the last dose) is not strictly necessary at once-weekly longevity doses because trough levels at this dosing interval may fall below the assay's reliable detection range. Some clinicians order a 24-hour post-dose level instead, targeting 3 to 7 ng/mL based on extrapolation from transplant data, though no validated therapeutic range exists for the longevity indication [9].

Annual follow-up labs are a minimum standard. Patients on long-term sirolimus should also have periodic monitoring for proteinuria given the drug's known effects on glomerular filtration, a finding documented in transplant-dose literature and potentially relevant at chronic low doses [14].

What Is the Total Annual Cost of a Rapamycin Longevity Protocol?

Adding up compounded medication, provider visits, and labs produces a realistic all-in annual cost estimate.

Compounded rapamycin at $60, $100/month equals $720, $1,200 per year in drug cost alone. Initial provider consultation at a longevity telehealth clinic runs $150, $350. Two follow-up visits per year add $100, $200. Baseline labs (CBC, CMP, lipids, HbA1c) through a direct-pay lab service such as Labcorp or Quest cost $80, $150 without insurance. One follow-up lab panel at 90 days adds another $80, $150.

Total first-year all-in cost: roughly $1,130, $2,050 for a standard protocol with appropriate monitoring. In subsequent years, without the initial consultation, the cost drops to $900, $1,600 annually. HSA funds can offset some or all of these costs if the plan document permits reimbursement for compounded prescriptions and telehealth visits [6].

By contrast, a longevity stack combining NMN (500 mg/day at $60/month), a prescription omega-3 such as icosapentaenoic acid (Vascepa 4 g/day at $200, $400/month with or without insurance), and a metformin prescription (generic, $4, $15/month) could run $264, $570 per month, or $3,168, $6,840 per year, for supplements plus drugs without counting provider fees. Rapamycin's once-weekly protocol is cost-competitive within that broader longevity-intervention market.

Is Compounded Rapamycin Worth the Cost Without Insurance Coverage?

The answer depends on individual risk tolerance, baseline health status, and confidence in the preclinical evidence base. The ITP mouse data are among the most reproducible findings in aging biology, replicated at three independent sites with different mouse strains [8]. The Mannick 2014 human data suggest immune rejuvenation at once-weekly mTOR inhibition [9]. The PEARL trial will provide the first properly powered human safety and biomarker dataset in healthy older adults [10].

For patients who have reviewed this evidence with a knowledgeable clinician, accept the off-label status, and can absorb $60, $150 per month without financial strain, the risk-benefit calculus may be favorable at ages 45 and older with no contraindications. For patients with active infections, upcoming surgery, or significant immunological conditions, the risk side of that calculus shifts materially.

Obtain a prescription only from a licensed provider who has reviewed your labs. Verify the compounding pharmacy's PCAB accreditation or 503B registration. Confirm the certificate of analysis on the first fill. Begin at 1 to 2 mg once weekly and reassess at 90 days with repeat labs before any dose increase above 3 mg weekly.